Skip to Content

Epinephrine Auto-Injectors

Last Updated: September 17, 2019
Status: Current

Products Affected - Description
    • Symjepi injection, Sandoz, 0.3 mg/0.3 mL, auto-injector, 2 count, NDC 00781-3442-20
    • Epinephrine injection, Amneal, 0.15 mg/0.15 mL, auto-injector, 2 count, NDC 00115-1695-49
    • Epinephrine injection, Amneal, 0.3 mg/0.3 mL, auto-injector, 2 count, NDC 00115-1694-49
Reason for the Shortage
    • Amneal has discontinued Adrenaclick. Amneal acquired Impax in 2018.
    • Mylan refused to provide availability information.
    • Sandoz launched Symjepi in January 2019 and product is available.
    • Teva has FDA approval for generic epinephrine.
Available Products
    • Auvi-Q injection, Kaleo, 0.1 mg/0.1 mL, auto-injector, 2 count, NDC 60842-0021-01
    • Auvi-Q injection, Kaleo, 0.15 mg/0.15 mL, auto-injector, 2 count, NDC 60842-0022-01
    • Auvi-Q injection, Kaleo, 0.3 mg/0.3 mL, auto-injector, 2 count, NDC 60842-0023-01
    • Epinephrine injection, Teva, 0.3 mg/0.3 mL, auto-injector, 2 count, NDC 00093-5986-27

Estimated Resupply Dates

    • Amneal has epinephrine 0.15 mg/0.15 mL and 0.3 mg/0.3 mL auto-injectors on allocation.
    • Sandoz has Symjepi available with expiration dates of April 2020 and July 2020.

Safety

    • FDA has extended the expiration dating for certain lots of EpiPen and some generic epinephrine auto-injectors. https://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm563360.htm

Updated

Updated September 17, 2019 by Stephen Andrews, PharmD, BCPS, Drug Information Specialist. Created May 3, 2018 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide